

# Our Comprehensive Product Portfolio



Facilitates a precision medicine approach for a broad spectrum of patients in a clinically relevant timeframe

	FoundationOne®CDx	FoundationOne®Liquid	FoundationOne®Heme	IHC
FDA-Approved	FDA-approved CDx for 17 targeted therapies	-	-	FDA-approved CDx for 2 immunotherapies
Target Tumor Types	All Solid Tumors	Liquid Biopsy (ctDNA) - All Solid Tumors	Hematologic Malignancies, Sarcomas (Soft Tissue + Bone)	Specific Solid Tumors
Number of Genes Analyzed	324 (DNA)	70 (DNA)	406 (DNA) 265 (RNA)	-
Genomic Signatures/ Biomarkers	Tumor Mutational Burden (TMB) Microsatellite Instability (MSI)	Microsatellite Instability (MSI)*	Tumor Mutational Burden (TMB) Microsatellite Instability (MSI)	PD-L1
Specimen†	FFPE Tissue	Peripheral Whole Blood	FFPE Tissue Bone Marrow Aspirate Peripheral Whole Blood	FFPE Tissue
	10 USS or 1 Block‡ + 1 H&E slide	2 Tubes of Peripheral Whole Blood	16 USS + 1 H&E Slide or 1 FFPE block or 2.5 mL Bone Marrow Aspirate or 1 filled EDTA Tube + 2.5 mL Paxgene Tube Peripheral Whole Blood	4 USS
Report Features	Point mutations, insertions/deletions, copy number alterations, select rearrangements	Point mutations, insertions/deletions, copy number alterations, select rearrangements	Point mutations, insertions/deletions, copy number alterations, rearrangements	Tumor Proportion Score (TPS) and/or Combined Positive Score (CPS) for approved/validated tumor types
Typical Turnaround Time§	< 2 weeks	< 2 weeks	2 weeks	5 days
List Price Per Test	\$5,800	\$5,800	\$7,200	\$250

Financial Assistance Program information is available at [access.foundationmedicine.com](https://access.foundationmedicine.com)

FFPE - Formalin-fixed, paraffin embedded tissue  
USS - Unstained slides

\* MSI status will be reported for samples determined to have high microsatellite instability  
† For full details, refer to specimen instructions at [www.foundationmedicine.com](https://www.foundationmedicine.com)

‡ FFPE Block is preferred  
§ Based on typical turnaround time from receipt of specimen

## About Foundation Medicine

Foundation Medicine is a world-leading molecular insights company offering a portfolio of comprehensive genomic profiling tests designed to ensure you have access to quality genomic insights regardless of cancer or specimen type.

### TO LEARN MORE:

Visit [www.foundationmedicine.com](http://www.foundationmedicine.com)

### TO ORDER:

Contact Client Services at 888.988.3639 or [client.services@foundationmedicine.com](mailto:client.services@foundationmedicine.com)



FoundationOne®CDx is a next-generation sequencing based *in vitro* diagnostic device for detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. For the complete intended use statement, including companion diagnostic indications, please see the FoundationOne CDx Technical Information, [www.foundationmedicine.com/flcdx](http://www.foundationmedicine.com/flcdx).



© 2019 Foundation Medicine, Inc. | Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.  
[www.foundationmedicine.com](http://www.foundationmedicine.com) | Tel. 888.988.3639 | Fax 617.418.2290 | MKT-0039-06